We describe an unusual case of recurrent, refractory anterior epistaxis in an 86-year-old man with two mechanical heart valves who was on permanentwarfarin therapy. His numerous episodes of epistaxis were incited by chronic nose-picking and strong nose-blowing, practices that he continued to engage in despite repeated medical advice to stop. Stopping his anticoagulation therapy was not considered as a management option because of an unacceptably high risk that this would lead to a thromboembolic event. Eventually, we temporarily sutured his nares closed, and his nosebleeds ceased. The suturing was performed in the ward with local anesthesia. This procedure was simple to perform, fairly well tolerated, easily reversible, and highly effective.
Introduction
Epistaxis is one of the most common reasons for emergency admissions to ENTwards. 1 When epistaxis occurs in a patient who has a coagulopathy or who is taking warfarin, it can be difficult to treat; the need to arrest the epistaxis must be balanced against the risk of inciting a thromboembolic event by stopping the warfarin. 2 Prevention of bleeding in such cases can be complicated by repeated nose-picking and strong nose-blowing in defiance of medical advice. In this article, we describe a novel method of preventing nasal trauma and promoting healing in a patient with a long history of recurrent, refractory epistaxis.
Case report
Thepatientwasan86-year-oldmanwhohadbeenrepeatedlypresenting to the ENT Department with refractory bilateral anterior epistaxis. He had two mechanical heart valves and was on permanent warfarin therapy, which made both the prevention and treatment of his epistaxis difficult. Prevention was also complicated by the fact that he engaged in chronic nose-picking and strong nose-blowing despite repeated advice to cease.
Previous hospitalizations. During a 4-year period, the patient had been admitted 13 times: twice in 2001, five times in 2003, and six times in 2004. His five most recent admissions had occurred within a period of 3 months.
Duringeachofthepatient'sadmissions,heunderwenta general examination, cardiovascular assessment, rigid nasendoscopy, and serology, which included measurements of the complete blood count, urea and electrolyte levels, liver function, and coagulation parameters, including the international normalized ratio (INR). During his series of admissions, his INR ranged from 2.7 to 5.0 (mean: 3.8; target: 3.5 to 4.5) and his hemoglobin level ranged from 8.1 to 12.2 g/dl (mean: 9.89; normal: 13.0 to 18.0). The INR was checked once daily, and the warfarin dose was titrated to achieve the target. During a hematology and cardiology consult, we were advised that stopping the warfarin or even lowering the target INR should not be attempted because doing so would raise the risk of a thromboembolic event to an unacceptably high level.
During most of the previous admissions, treatment involved cauterization and/or nasal packing with a Merocel sponge:
• On four occasions, the patient underwent both cauterization and nasal packing with a Merocel sponge.
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Figure 1. Coronal CTs show the masses (arrows) in the left (A) and right (B) nasal cavities. Note the lack of bone invasion.
fractions). However, despite delivery of the full course of radiotherapy, the size of the left nasal plasmacytoma did not change. Three months after the completion of radiotherapy, it was removed endoscopically. Pathology confirmed the mass as a persistent plasmacytoma. Despite a prolonged healing time, the patient exhibited no evidence of persistence or recurrence following surgical excision at 42 months of follow-up.
Discussion
Extramedullary plasmacytomas are monoclonal B-cell tumors that present as localized masses but do not meet the criteria for multiple myeloma because they do not involve the bone marrow. They account for approximately 3% of all plasma cell malignancies and less than 1 % of all head and neck cancers. 1 • 3 , 5 More than 85% of extramedullary plasmacytomas are found in the upper aerodigestive tract. 2 • 5 The most common symptoms at presentation are nasal discharge, nasal obstruction, and epistaxis. 2 • 5 The clinical features of extramedullary plasmacytoma include a median age at diagnosis of 55 years, a 3:1 male preponderance, and the presence of multiple lesions in about 10% of cases. 2 Progression to multiple myeloma occurs in less than 30% of cases. 2 • 4 When progression does occur, it is more common in patients with highgrade tumors. 1 • 5 Reported 5-and 10-year survival rates are approximately 80 and 67%, respectively. 2 • 5 • 6 Treatment options for the potential cure of extramedullary plasmacytoma include surgery and radiation therapy. Radiation therapy is the more popular treat-224 • www.entjournal.com ment because it is associated with excellent response rates (>90%) and low morbidity.1-2 The British Society for Haematology has issued a set of guidelines for the diagnosis and treatment of extramedullary plasmacytoma. 2 The Society recommends initial radiation treatment with 40 Gy in 20 fractions with a 2-cm margin for tumors smaller than 5 cm, and 50 Gy in 25 fractions for larger tumors. Regional cervical lymph nodes should be irradiated only if they are directly involved or if there is a high risk of spread.
Overall, local recurrence rates following adequate radiation are less than 7%. 7 Most treatment failures are attributable to large tumor size (>5 cm) at the initiation of radiotherapy. 2 • 4 • 7 Surgery is an option when widely clear surgical margins can be obtained without causing surgical morbidity. 2 • 5 When clear margins are obtained, the probability of local control with surgery is similar to that with radiation therapy. 5 • 6 Several investigators have suggested that the treatment ofextramedullaryplasmacytomawithadjuvantchemotherapy improves neither local control nor survival. 3 • 4 • 7 Current thought is that chemotherapy should be used for most cases of disseminated disease or conversion to multiple myeloma and in some cases of recurrence. The most significant tumor characteristic that may favor the addition of chemotherapy is histologic grade; high-grade tumors are associated with a higher risk of eventual disease dissemination or conversion to multiple myeloma.1. 3 , 5 Systemic chemotherapy can delay the development of multiple myeloma, and it may prolong survival in patients who eventually develop it. In addition to extramedullary plasmacytoma, our patient had rheumatoid arthritis. Prior to the diagnosis of extramedullaryplasmacytoma, his arthritis had been treated for several years with the immunosuppressants methotrexate and cyclosporine and occasionally with prednisone.An increased risk of transplantation-related malignancies has been documented in patients who have undergone long-term immunosuppression. 8 The most common of these malignancies are the nonmelanoma skin cancers and non-Hodgkin lymphoma. It is interesting that transplant-associated non-Hodgkin lymphomas are usually associated with EBV infection in extranodal sites; our patient also had an EBV infection. 8 Also, an association between cyclosporine treatment and the development of malignancy has been known for years. 8 In conclusion, the currently published guidelines on the treatment of extramedullaryplasmacytoma suggest that radiotherapy is the best initial treatment for the vast majority of cases. 2 Surgical excision is an option when negative margins can be obtained without causing significant surgical morbidity; it is also an option for patients with persistent disease. Recent evidence suggests that complete surgical resection with clear margins and close follow-up is a legitimate primary treatment option. 3 
